$DNA

Coen Steven P. sold $36K of DNA

Coen Steven P. (See remarks) sold 2,403 shares of Ginkgo Bioworks Holdings, Inc. (DNA) at $15.00 on 2026-10-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Coen Steven P.
Published Oct 7, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DNA
Neutral
high confidence
Mentioned
$DNA
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DNANeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock materially, but it provides transparency for investors monitoring insider activity.

02

Market read

Routine insider sale with limited trading relevance; serves primarily as a compliance disclosure.

03

What to watch

The insider still holds a sizable position (≈0.5% of shares), indicating continued confidence.

Relevance 2/10Novelty 2/10Timing: after-hours filing today

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan allows pre‑arranged sales, often used for portfolio rebalancing.

Company-level read

Ticker impact

$DNANeutralHigh confidence
Context

Officer Coen Steven P. sold 2,403 shares of Ginkgo Bioworks (DNA) for $36,045 via a 10b5‑1 plan, reducing his stake to 49,448 shares.

Expected impact

likely modest downward pressure as the market prices the insider sale

Evidence & confidence

The sale is small relative to float and disclosed via a Form 4, typical of routine 10b5‑1 transactions; no material change in ownership.

Market effects

Minimal impact on synthetic biology sector; insider sales are common and not indicative of broader trends.

None

None

Counterpoint

The sale could be a routine liquidity event, not a bearish signal; investors may ignore it.

Key entities

  • Ginkgo Bioworks Holdings, Inc.

    Synthetic biology company listed on NASDAQ under ticker DNA.

  • Coen Steven P.

    Company officer executing a 10b5‑1 sale of DNA shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DNAMed

A GT investigation examines the funding, government ties and questionable business practices of seven US entities subject to China’s countermeasures

China’s Ministry of Commerce announced countermeasures against seven US entities, including Applied DNA Sciences (now BNB Plus Corp), Stratum Reservoir, Altana Technologies, Responsible Business Alliance, Verite Group, Human Rights in China, and Compliance Testing LLC, citing US sanctions over alleged forced labor in Xinjiang. The article links their roles to cotton traceability testing, AI supply-chain mapping, compliance services, and related government contracts.

$DNAMed

Ginkgo Bioworks Q2 Earnings Call Highlights

Ginkgo Bioworks (NYSE:DNA) reported first-half 2026 cash burn of $93M, down 3% from $96M a year earlier. Management said Q1 cash burn included a $14M Google Cloud payment tied to an amended 2025 commitment that cut future minimums by over $100M and extended the term to six years. Ginkgo expanded its Nebula lab to 105 racks and raised $17M via an ATM.

$DNAMed

Ginkgo Bioworks Reports Second Quarter 2026 Results, Wins Government Contracts to Build Autonomous Labs at MIT, Caltech, Northwestern, and University of…

Ginkgo Bioworks Holdings, Inc. (DNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ginkgo Bioworks Reports Second Quarter 2026 Results, Wins Government Contracts to Build Autonomous Labs at MIT, Caltech, Northwestern, and University of Maryland Ginkgo provides an update on its second quarter financial results and its continued efforts to scale Nebu

$DNAMed

Researchers are building AI-powered robot labs. What does this mean for science?

NPR reports that Ginkgo Bioworks in Boston is developing an “autonomous lab” where AI directs robots to run experiments, including drug discovery, fertilizer microbes, and protein design. Founders say AI is moving from automating tasks to generating hypotheses, including an OpenAI collaboration using GPT‑5 to design a cell-free protein synthesis reaction. Stanford’s Drew Endy warns of biosecurity and skills-loss risks.

$DNAMed

Researchers are building AI-powered robot labs. What does this mean for science?

NPR reports that researchers at Ginkgo Bioworks in Boston are building “autonomous labs” where AI and robots handle tasks such as pipetting, scheduling experiments, and even generating hypotheses. Founders Jason Kelly and Reshma Shetty say AI is being used to design experiments overnight and to collaborate with OpenAI on cell-free protein synthesis. Stanford’s Drew Endy warns about biosecurity and loss of scientific know-how.